Since its inception in 2011, Fujifilm Diosynth Biotechnologies has added capabilities and single-use production capacity for mammalian-derived product manufacturing, upgraded development and pilot-scale microbial laboratories, and installed advanced analytical instrumentation.

Eisai has launched a new dry syrup formulation of its Alzheimer's disease treatment Aricept (donepezil hydrochloride) in Japan.

The Alliance for Fair Trade with India is seeking action to resolve discriminatory trade practices and improved protection of intellectual property rights.

The move is part of a strategy to cultivate innovation in key regions.

Serelaxin, to treat acute heart failure, is the second Novartis drug to get new designation from FDA.

Entries open to any company across three categories - formulation, process development and best packaging.

Combination product design takes second prize in the National Collegiate Inventors and Innovators Alliance Biomedical Engineering contest.

Global program seeks to confirm biosimilarity to support regulatory submissions in the US and EU.

NIH awards $12.7 million for collaborations between nine academic research groups and pharmaceutical industry partners to explore new treatments.

New production capabilities in Normandy, France will include a cleanroom.

A screening method predicts delamination in primary packaging.

Semi-automatic technology aids egg-based influenza vaccine production in smaller facility footprints.

The multimillion investment in a facility in Cambridge is part of the company's move to create strategic global R&D centers in the UK, US and Sweden.

A proposed deal with Aspen includes the GSK’s site in Notre-Dame-de-Bondeville, France.

The settlement comes after a nearly 10-year legal battle in which Pfizer and Nycomed (now part of Takeda) sought to enforce the patent for its blockbuster acid reflux medicine.

The billion-dollar deal provides strengthens J&J’s oncology portfolio.

The move follows rejection of Elan shareholders of certain key deals and withdrawal of Royalty Pharma bid.

PSL has developed a microsphere refiner for microsphere formulation, from small scale processes to commercial production.

The US Supreme Court ruled that naturally occurring isolated biological material is not patentable, but a synthetic version of gene material may be patented.

Eli Lilly has discontinued its Phase II study, which investigated the company's beta secretase (BACE) inhibitor, LY2886721, as a treatment for Alzheimer's disease. The decision to terminate the study was because of abnormal liver biochemical tests identified during routine monitoring.

Catalent is investing nearly $35 million in a major expansion of its controlled-release drug manufacturing facility in Winchester, Kentucky.

Almac has announced expansion of its UK facility and a new non-GMP drug development facility at the Craigavon site, representing an investment of $21.5 million.

ISPE study reveals quality systems of manufacturing as the leading cause of drug shortages.

USP appoints regulatory experts to elemental impurities implementation advisory group.

One employee is dismissed, another has resigned, and three others are put on administrative leave.

Elan urges its shareholders to reject bid in an upcoming meeting on June 17.

The multimillion-dollar deal focuses oncology.

EMA's revised guideline on biosimilars containing biotechnology-derived proteins is published for public consultation.